{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T10:18:53Z","timestamp":1760955533444},"reference-count":32,"publisher":"Japanese Society of Internal Medicine","issue":"2","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Intern. Med."],"published-print":{"date-parts":[[2015]]},"DOI":"10.2169\/internalmedicine.54.3066","type":"journal-article","created":{"date-parts":[[2015,1,14]],"date-time":"2015-01-14T17:10:01Z","timestamp":1421255401000},"page":"119-126","source":"Crossref","is-referenced-by-count":6,"title":["Safety and Efficacy of Partial Splenic Embolization in Telaprevir-based Triple Therapy for Chronic Hepatitis C"],"prefix":"10.2169","volume":"54","author":[{"given":"Chisa","family":"Kondo","sequence":"first","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masanori","family":"Atsukawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Akihito","family":"Tsubota","sequence":"additional","affiliation":[{"name":"Core Research Facilities for Basic Science, Research Center for Medical Sciences, The Jikei University School of Medicine, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Noritomo","family":"Shimada","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Shinmatsudo Central General Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Abe","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine Katsushika Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Norio","family":"Itokawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ai","family":"Nakagawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Takeshi","family":"Fukuda","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoko","family":"Matsushita","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhisa","family":"Nakatsuka","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiaki","family":"Kawamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Katsuhiko","family":"Iwakiri","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology, Department of Internal Medicine, Nippon Medical School Chiba Hokusoh Hospital, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshio","family":"Aizawa","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, The Jikei University School of Medicine Katsushika Medical Center, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Choitsu","family":"Sakamoto","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology, Department of Internal Medicine, Nippon Medical School, Japan"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"962","reference":[{"key":"1","doi-asserted-by":"crossref","unstructured":"1. Thomas DL. Global control of hepatitis C: where challenge meets opportunity. Nat Med 19: 850-858, 2013.","DOI":"10.1038\/nm.3184"},{"key":"2","doi-asserted-by":"crossref","unstructured":"2. Kiyosawa K, Sodeyama T, Tanaka E, et al. Interrelationship of blood transfusion, non-A, non-B hepatitis and hepatocellular carcinoma: analysis by detection of antibody to hepatitis C virus. Hepatology 12: 671-675, 1990.","DOI":"10.1002\/hep.1840120409"},{"key":"3","doi-asserted-by":"crossref","unstructured":"3. Degos F, Christidis C, Ganne-Carrie N, et al. Hepatitis C virus related cirrhosis: time to occurrence of hepatocellular carcinoma and death. Gut 47: 131-136, 2000.","DOI":"10.1136\/gut.47.1.131"},{"key":"4","doi-asserted-by":"crossref","unstructured":"4. Hoofnagle JH, Mullen KD, Jones DB, et al. Treatment of chronic non-A, non-B hepatitis with recombinant human alpha interferon. A preliminary report. N Engl J Med 315: 1575-1578, 1986.","DOI":"10.1056\/NEJM198612183152503"},{"key":"5","doi-asserted-by":"crossref","unstructured":"5. Cardoso AC, Moucari R, Figueiredo-Mendes C, et al. Impact of peginterferon and ribavirin therapy on hepatocellular carcinoma: incidence and survival in hepatitis C patients with advanced fibrosis. J Hepatol 52: 652-657, 2010.","DOI":"10.1016\/j.jhep.2009.12.028"},{"key":"6","doi-asserted-by":"crossref","unstructured":"6. Ikeda K, Saitoh S, Arase Y, et al. Effect of interferon therapy on hepatocellular carcinogenesis in patients with chronic hepatitis type C: A long-term observation study of 1,643 patients using statistical bias correction with proportional hazard analysis. Hepatology 29: 1124-1130, 1999.","DOI":"10.1002\/hep.510290439"},{"key":"7","doi-asserted-by":"crossref","unstructured":"7. Kasahara A, Hayashi N, Mochizuki K, et al. Risk factors for hepatocellular carcinoma and its incidence after interferon treatment in patients with chronic hepatitis C. Osaka Liver Disease Study Group. Hepatology 27: 1394-1402, 1998.","DOI":"10.1002\/hep.510270529"},{"key":"8","doi-asserted-by":"crossref","unstructured":"8. Everson GT, Hoefs JC, Seeff LB, et al. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial. Hepatology 44: 1675-1684, 2006.","DOI":"10.1002\/hep.21440"},{"key":"9","doi-asserted-by":"crossref","unstructured":"9. Manns MP, McHutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 358: 958-965, 2001.","DOI":"10.1016\/S0140-6736(01)06102-5"},{"key":"10","doi-asserted-by":"crossref","unstructured":"10. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 347: 975-982, 2002.","DOI":"10.1056\/NEJMoa020047"},{"key":"11","doi-asserted-by":"crossref","unstructured":"11. Bruno S, Shiffman ML, Roberts SK, et al. Efficacy and safety of peginterferon alfa-2a (40KD) plus ribavirin in hepatitis C patients with advanced fibrosis and cirrhosis. Hepatology 51: 388-397, 2010.","DOI":"10.1002\/hep.23340"},{"key":"12","doi-asserted-by":"crossref","unstructured":"12. Backus LI, Boothroyd DB, Phillips BR, Mole LA. Predictors of response of US veterans to treatment for the hepatitis C virus. Hepatology 46: 37-47, 2007.","DOI":"10.1002\/hep.21662"},{"key":"13","doi-asserted-by":"crossref","unstructured":"13. Helbling B, Jochum W, Stamenic I, et al. HCV-related advanced fibrosis\/cirrhosis: randomized controlled trial of pegylated interferon alpha-2a and ribavirin. J Viral Hepat 13: 762-769, 2006.","DOI":"10.1111\/j.1365-2893.2006.00753.x"},{"key":"14","doi-asserted-by":"crossref","unstructured":"14. Foruny JR, Blazquez J, Moreno A, et al. Safe use of pegylated interferon\/ribavirin in hepatitis C virus cirrhotic patients with hypersplenism after partial splenic embolization. Eur J Gastroenterol Hepatol 17: 1157-1164, 2005.","DOI":"10.1097\/00042737-200511000-00002"},{"key":"15","doi-asserted-by":"crossref","unstructured":"15. Miyake Y, Ando M, Kaji E, Toyokawa T, Nakatsu M, Hirohata M. Partial splenic embolization prior to combination therapy of interferon and ribavirin in chronic hepatitis C patients with thrombocytopenia. Hepatol Res 38: 980-986, 2008.","DOI":"10.1111\/j.1872-034X.2008.00357.x"},{"key":"16","doi-asserted-by":"crossref","unstructured":"16. Jacobson IM, McHutchison JG, Dusheiko G, et al. Telaprevir for previously untreated chronic hepatitis C virus infection. N Engl J Med 364: 2405-2416, 2011.","DOI":"10.1056\/NEJMoa1012912"},{"key":"17","doi-asserted-by":"crossref","unstructured":"17. Zeuzem S, Andreone P, Pol S, et al. Telaprevir for retreatment of HCV infection. N Engl J Med 364: 2417-2428, 2011.","DOI":"10.1056\/NEJMoa1013086"},{"key":"18","doi-asserted-by":"crossref","unstructured":"18. Sherman KE, Flamm SL, Afdhal NH, et al. Response-guided telaprevir combination treatment for hepatitis C virus infection. N Engl J Med 365: 1014-1024, 2011.","DOI":"10.1056\/NEJMoa1014463"},{"key":"19","doi-asserted-by":"crossref","unstructured":"19. Tanaka Y, Kurosaki M, Nishida N, et al. Genome-wide association study identified ITPA\/DDRGK1 variants reflecting thrombocytopenia in pegylated interferon and ribavirin therapy for chronic hepatitis C. Hum Mol Genet 20: 3507-3516, 2011.","DOI":"10.1093\/hmg\/ddr249"},{"key":"20","doi-asserted-by":"crossref","unstructured":"20. Adinolfi LE, Giordano MG, Andreana A, et al. Hepatic fibrosis plays a central role in the pathogenesis of thrombocytopenia in patients with chronic viral hepatitis. Br J Haematol 113: 590-595, 2001.","DOI":"10.1046\/j.1365-2141.2001.02824.x"},{"key":"21","doi-asserted-by":"crossref","unstructured":"21. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum aminotransferase levels and platelet counts as predictors of degree of fibrosis in chronic hepatitis C virus infection. Am J Gastroenterol 96: 3142-3146, 2001.","DOI":"10.1111\/j.1572-0241.2001.05268.x"},{"key":"22","doi-asserted-by":"crossref","unstructured":"22. Tahara H, Takagi H, Sato K, et al. A retrospective cohort study of partial splenic embolization for antiviral therapy in chronic hepatitis C with thrombocytopenia. J Gastroenterol 46: 1010-1019, 2011.","DOI":"10.1007\/s00535-011-0407-9"},{"key":"23","doi-asserted-by":"crossref","unstructured":"23. Takahara M, Miyake Y, Miyatake H, et al. Partial splenic embolization facilitates the adherence to peginterferon in chronic hepatitis C with thrombocytopenia. Intern Med 50: 2731-2736, 2011.","DOI":"10.2169\/internalmedicine.50.6143"},{"key":"24","doi-asserted-by":"crossref","unstructured":"24. Akuta N, Suzuki F, Seko Y, et al. Determinants of response to triple therapy of telaprevir, peginterferon, and ribavirin in previous non-responders infected with HCV genotype 1. J Med Virol 84: 1097-1105, 2012.","DOI":"10.1002\/jmv.23262"},{"key":"25","doi-asserted-by":"crossref","unstructured":"25. Chayama K, Hayes CN, Abe H, et al. IL28B but not ITPA polymorphism is predictive of response to pegylated interferon, ribavirin, and telaprevir triple therapy in patients with genotype 1 hepatitis C. J Infect Dis 204: 84-93, 2011.","DOI":"10.1093\/infdis\/jir210"},{"key":"26","doi-asserted-by":"crossref","unstructured":"26. Thompson AJ, McHutchison JG. Will IL28B polymorphism remain relevant in the era of direct-acting antiviral agents for hepatitis C virus? Hepatology 56: 373-381, 2012.","DOI":"10.1002\/hep.25792"},{"key":"27","doi-asserted-by":"crossref","unstructured":"27. Tsubota A, Shimada N, Atsukawa M, et al. Impact of IL28B polymorphisms on 24-week telaprevir-based combination therapy for Asian chronic hepatitis C patients with hepatitis C virus genotype 1b. J Gastroenterol Hepatol 29: 144-150, 2014.","DOI":"10.1111\/jgh.12402"},{"key":"28","doi-asserted-by":"crossref","unstructured":"28. Hezode C, Fontaine H, Dorival C, et al. Triple therapy in treatment-experienced patients with HCV-cirrhosis in a multicentre cohort of the French Early Access Programme (ANRS CO20-CUPIC) - NCT01514890. J Hepatol 59: 434-441, 2013.","DOI":"10.1016\/j.jhep.2013.04.035"},{"key":"29","doi-asserted-by":"crossref","unstructured":"29. Ogawa E, Furusyo N, Nakamuta M, et al. Telaprevir-based triple therapy for chronic hepatitis C patients with advanced fibrosis: a prospective clinical study. Aliment Pharmacol Ther 38: 1076-1085, 2013.","DOI":"10.1111\/apt.12494"},{"key":"30","doi-asserted-by":"crossref","unstructured":"30. Fellay J, Thompson AJ, Ge D, et al. ITPA gene variants protect against anaemia in patients treated for chronic hepatitis C. Nature 464: 405-408, 2010.","DOI":"10.1038\/nature08825"},{"key":"31","doi-asserted-by":"crossref","unstructured":"31. Ochi H, Maekawa T, Abe H, et al. ITPA polymorphism affects ribavirin-induced anemia and outcomes of therapy--a genome-wide study of Japanese HCV virus patients. Gastroenterology 139: 1190-1197, 2010.","DOI":"10.1053\/j.gastro.2010.06.071"},{"key":"32","doi-asserted-by":"crossref","unstructured":"32. Thompson AJ, Clark PJ, Singh A, et al. Genome-wide association study of interferon-related cytopenia in chronic hepatitis C patients. J Hepatol 56: 313-319, 2012.","DOI":"10.1016\/j.jhep.2011.04.021"}],"container-title":["Internal Medicine"],"original-title":[],"language":"en","deposited":{"date-parts":[[2017,6,22]],"date-time":"2017-06-22T23:42:26Z","timestamp":1498174946000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.jstage.jst.go.jp\/article\/internalmedicine\/54\/2\/54_54.3066\/_article"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015]]},"references-count":32,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015]]}},"URL":"https:\/\/doi.org\/10.2169\/internalmedicine.54.3066","relation":{},"ISSN":["0918-2918","1349-7235"],"issn-type":[{"value":"0918-2918","type":"print"},{"value":"1349-7235","type":"electronic"}],"subject":[],"published":{"date-parts":[[2015]]}}}